Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orchestra BioMed Holdings (OBIO) Net Income (2022 - 2025)

Historic Net Income for Orchestra BioMed Holdings (OBIO) over the last 4 years, with Q3 2025 value amounting to -$20.8 million.

  • Orchestra BioMed Holdings' Net Income fell 3501.88% to -$20.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$75.1 million, marking a year-over-year decrease of 3371.97%. This contributed to the annual value of -$60.9 million for FY2024, which is 2788.26% down from last year.
  • As of Q3 2025, Orchestra BioMed Holdings' Net Income stood at -$20.8 million, which was down 3501.88% from -$19.4 million recorded in Q2 2025.
  • Orchestra BioMed Holdings' 5-year Net Income high stood at -$5.1 million for Q1 2022, and its period low was -$20.8 million during Q3 2025.
  • Moreover, its 4-year median value for Net Income was -$13.4 million (2024), whereas its average is -$13.5 million.
  • Per our database at Business Quant, Orchestra BioMed Holdings' Net Income crashed by 12513.65% in 2023 and then tumbled by 1335.15% in 2024.
  • Orchestra BioMed Holdings' Net Income (Quarter) stood at -$9.8 million in 2022, then decreased by 15.72% to -$11.4 million in 2023, then plummeted by 42.05% to -$16.2 million in 2024, then decreased by 28.93% to -$20.8 million in 2025.
  • Its last three reported values are -$20.8 million in Q3 2025, -$19.4 million for Q2 2025, and -$18.8 million during Q1 2025.